Clinical implications of the third universal definition of myocardial infarction

Postgraduate Medical Journal

Volumn 90, Issue 1067, 2014, Pages 502-510

  White, Harvey D ^a   Thygesen, Kristian ^b   Alpert, Joseph S ^c   Jaffe, Allan S ^d  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; EVIDENCE BASED PRACTICE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE ASSAY; RISK FACTOR; STENT THROMBOSIS;

EID: 84906309192     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2012-302976rep     Document Type: Article

References (29)

1. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC-ACC-AHA-WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
2. The universal definition of MI re-emphasised the importance of troponins and recommended that five types of MI be defined.
3. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.
4. The Third Universal Definition of MI consensus statement defined clinical criteria for the diagnosis of MI corresponding to contemporary management. New ECG and imaging criteria are added, the definitions for the five types of MI are refined, and the presence of angiographic intracoronary thrombus is added as a criterion.
5. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-13.
6. The first international consensus for a new definition of MI, recommending troponins as central to the diagnosis.
7. Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 2008;118:2200-6.
8. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011;57:2406-8.
9. A classification of the six potential pathobiological causes of troponin elevations is defined. Potential mechanisms include myocyte necrosis, apoptosis, normal myocyte turnover, cellular release of troponin degradation products, increased cell wall permeability, and release of membranous blebs.
10. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations. J Am Coll Cardiol 2012;60:2427-63.
11. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
12. Jaffe AS, Apple FS, Morrow DA, et al. Being rational about (im) precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. Clin Chem 2010;56:941-3.
13. Biener M, Mueller M, Vafaie M, et al. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol 2012 [Epub ahead of print]
14. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31:2197-204.
15. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252-7.
16. A publication by the European Biochemical Working Group with recommendations on how to use high sensitivity troponins for the diagnosis of MI.
17. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84.
18. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-64.
19. White HD, Reynolds HR, Carvalho AC, et al. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the occluded artery trial (OAT) cohort. Am Heart J 2012;163:563-71.
20. Jaffe AS, Apple FS, Lindahl B, et al. Why all the struggle about CK-MB and PCI? Eur Heart J 2012;33:1046-8.
21. An editorial discussing why CK-MB should no longer be used for the diagnosis of MI associated with PCI (type 4a)
22. White HD. The prequel: defining prognostically important criteria in the periprocedural PCI troponin saga. Circ Cardiovas Intervent 2012;5:142-5.
23. An editorial discussing many of the issues in relation to a type 4a MI including the need for a stable baseline and the need for more data with respect to prognosis using troponins and associated ischaemia and/or angiographic complications.
24. Leonardi S, Thomas L, Neely ML, et al. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. J Am Coll Cardiol 2012;60:2296-304.
25. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163:182-90 e4.
26. A pooled analysis of two large negative clinical trials testing the intravenous P2Y12 inhibitor cangrelor compared with clopidogrel. On re-analysis using the universal definition of MI there was a significant reduction in ischaemic events leading to a new large trial.
27. Bhatt DL, Stone GW, Mahaffey KW, et al. for the CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013; 368:1303-13.
28. Mendis S, Thygesen K, Kuulasmaa K, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol 2011;40:139-46.
29. The WHO has a played a leading role in developing standard criteria for the diagnosis of MI since the early 1970s. This article presents a revision of the WHO definition taking into account the universal definition and the common situation in resource constrained settings where biomarkers and ECGs may not be available.